[go: up one dir, main page]

WO2009004995A1 - 生理活性物質を定着および発現させる方法 - Google Patents

生理活性物質を定着および発現させる方法 Download PDF

Info

Publication number
WO2009004995A1
WO2009004995A1 PCT/JP2008/061709 JP2008061709W WO2009004995A1 WO 2009004995 A1 WO2009004995 A1 WO 2009004995A1 JP 2008061709 W JP2008061709 W JP 2008061709W WO 2009004995 A1 WO2009004995 A1 WO 2009004995A1
Authority
WO
WIPO (PCT)
Prior art keywords
active substance
physiologically active
fixing
administered
expressing
Prior art date
Application number
PCT/JP2008/061709
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Yoneyama
Kenji Suzuki
Original Assignee
Stelic Institute Of Regenerative Medicine, Stelic Institute & Co.
Niigata University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP18188952.8A priority Critical patent/EP3456357A1/en
Priority to JP2009521604A priority patent/JP5547964B2/ja
Priority to EP15201508.7A priority patent/EP3034095B1/en
Priority to EP21163980.2A priority patent/EP3895737A1/en
Priority to US12/666,983 priority patent/US20100329993A1/en
Priority to EP20170385.7A priority patent/EP3711755A1/en
Application filed by Stelic Institute Of Regenerative Medicine, Stelic Institute & Co., Niigata University filed Critical Stelic Institute Of Regenerative Medicine, Stelic Institute & Co.
Priority to EP08790674A priority patent/EP2172226A4/en
Publication of WO2009004995A1 publication Critical patent/WO2009004995A1/ja
Priority to US14/158,607 priority patent/US20140135379A1/en
Priority to US15/241,830 priority patent/US20160355818A1/en
Priority to US16/269,359 priority patent/US10689650B2/en
Priority to US16/869,812 priority patent/US11485974B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/396—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having three-membered rings, e.g. aziridine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nutrition Science (AREA)

Abstract

本発明は、標的とする粘膜下組織に生理活性物質を投与することにより、該組織特異的に生理活性物質を定着および発現させる方法を提供する。すなわち本発明者らは、粘膜下組織に対し、担体を利用せず直接生理活性物質を投与することによって、該生理活性物質が消失あるいは拡散したりせず、安全かつ効果的に長期間にわたって投与局所に定着し、さらにはリザーバーのように働き効果を発揮することを見出した。また上述のようにして投与された生理活性物質は投与臓器以外の他の臓器には影響を及ぼさず、治療効果を有することも見出した。
PCT/JP2008/061709 2007-06-29 2008-06-27 生理活性物質を定着および発現させる方法 WO2009004995A1 (ja)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2009521604A JP5547964B2 (ja) 2007-06-29 2008-06-27 生理活性物質を定着および発現させる方法
EP15201508.7A EP3034095B1 (en) 2007-06-29 2008-06-27 Method of fixing and expressing physiologically active substance
EP21163980.2A EP3895737A1 (en) 2007-06-29 2008-06-27 Method of fixing and expressing physiologically active substance
US12/666,983 US20100329993A1 (en) 2007-06-29 2008-06-27 Method of fixing and expressing physiologically active substance
EP20170385.7A EP3711755A1 (en) 2007-06-29 2008-06-27 Method of fixing and expressing physiologically active substance
EP18188952.8A EP3456357A1 (en) 2007-06-29 2008-06-27 Method of fixing and expressing physiologically active substance
EP08790674A EP2172226A4 (en) 2007-06-29 2008-06-27 METHOD FOR FIXING AND EXPRESSING A PHYSIOLOGICALLY ACTIVE SUBSTANCE
US14/158,607 US20140135379A1 (en) 2007-06-29 2014-01-17 Method of fixing and expressing physiologically active substance
US15/241,830 US20160355818A1 (en) 2007-06-29 2016-08-19 Method of fixing and expressing physiologically active substance
US16/269,359 US10689650B2 (en) 2007-06-29 2019-02-06 Method of fixing and expressing physiologically active substance
US16/869,812 US11485974B2 (en) 2007-06-29 2020-05-08 Method of fixing and expressing physiologically active substance

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-171361 2007-06-29
JP2007171361 2007-06-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/666,983 A-371-Of-International US20100329993A1 (en) 2007-06-29 2008-06-27 Method of fixing and expressing physiologically active substance
US14/158,607 Continuation US20140135379A1 (en) 2007-06-29 2014-01-17 Method of fixing and expressing physiologically active substance

Publications (1)

Publication Number Publication Date
WO2009004995A1 true WO2009004995A1 (ja) 2009-01-08

Family

ID=40226041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061709 WO2009004995A1 (ja) 2007-06-29 2008-06-27 生理活性物質を定着および発現させる方法

Country Status (5)

Country Link
US (5) US20100329993A1 (ja)
EP (7) EP3895737A1 (ja)
JP (1) JP5547964B2 (ja)
ES (1) ES2685636T3 (ja)
WO (1) WO2009004995A1 (ja)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014013535A1 (ja) * 2012-07-17 2014-01-23 株式会社ステリック再生医科学研究所 粘膜治癒促進剤
JP2015515886A (ja) * 2012-05-01 2015-06-04 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 経皮挿入するための先端装填型マイクロニードルアレイ
WO2018105708A1 (ja) 2016-12-07 2018-06-14 株式会社ステリック再生医科学研究所 慢性疾患の治療及び予防用医薬組成物
US10441768B2 (en) 2015-03-18 2019-10-15 University of Pittsburgh—of the Commonwealth System of Higher Education Bioactive components conjugated to substrates of microneedle arrays
US10646579B2 (en) 2015-11-04 2020-05-12 Tme Therapeutics Inc. Complex comprising RNAi molecule and N-acetylated chitosan
EP3673910A1 (en) * 2007-12-27 2020-07-01 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Sugar chain-related gene and use thereof
US11684763B2 (en) 2015-10-16 2023-06-27 University of Pittsburgh—of the Commonwealth System of Higher Education Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices
US11744927B2 (en) 2009-10-23 2023-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
US11744889B2 (en) 2016-01-05 2023-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Skin microenvironment targeted delivery for promoting immune and other responses
US12214150B2 (en) 2019-05-16 2025-02-04 University of Pittsburgh—of the Commonwealth System of Higher Education Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery
EP4397310A4 (en) * 2021-08-30 2025-06-25 TME Therapeutics Inc. Pharmaceutical composition for suppressing cancer invasion and method for suppressing cancer invasion

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017370937A1 (en) 2016-12-07 2019-05-30 Biora Therapeutics, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183934A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0454352B2 (ja) 1983-01-18 1992-08-31 Sanyo Electric Co
JPH09505575A (ja) 1993-11-23 1997-06-03 ローン−プーラン・ロレ・ソシエテ・アノニム イン・ビボでの治療性生産物の生産のための組成物
JP2003516365A (ja) 1999-12-08 2003-05-13 フアルマコンセプツ・エイビー 核酸送達系
JP2005503199A (ja) 2001-06-14 2005-02-03 クック インコーポレーテッド 脈管内フィルター
WO2005063293A1 (ja) * 2003-12-26 2005-07-14 Masatoshi Hagiwara Sr蛋白質のリン酸化制御方法、および、sr蛋白質の活性制御剤を有効成分とする抗ウイルス剤
JP2005538943A (ja) 2002-05-03 2005-12-22 エフエムシー バイオポリマー エイエス 非ウイルス性遺伝子送達システム
JP2007502616A (ja) * 2003-08-18 2007-02-15 アイシス ファーマシューティカルズ インコーポレイテッド ジアシルグリセロールアシルトランスフェラーゼ２発現の調節
JP2007119498A (ja) 2001-11-05 2007-05-17 Seikagaku Kogyo Co Ltd 上皮膨隆高の維持用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054352A (en) * 1975-08-25 1977-10-18 Rudin Marvin B Electrical power take-off unit for cigarette lighter socket of vehicle
US5695998A (en) 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6448081B1 (en) * 2001-05-07 2002-09-10 Isis Pharmaceuticals, Inc. Antisense modulation of interleukin 12 p40 subunit expression
PT1023903E (pt) * 1999-01-26 2004-04-30 Akzo Nobel Nv Utilizacao de bacterias vivas atenuadas para o fabrico de uma vacina submucosa
FR2797274B1 (fr) 1999-08-02 2003-09-05 Agronomique Inst Nat Rech Gene mutant de la famille gras, et plantes a developpement reduit comprenant ledit gene
US20070026394A1 (en) * 2000-02-11 2007-02-01 Lawrence Blatt Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
ATE389393T1 (de) * 2000-06-06 2008-04-15 Lequio Pharma Co Ltd Medizinisches kombinationspräparat zur behandlung von verletztem abnormem gewebe
WO2002044321A2 (en) * 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
US7008626B2 (en) * 2001-11-05 2006-03-07 Seikagaku Corporation Medical composition for protuberance of epithelium
US20050106729A1 (en) * 2002-05-03 2005-05-19 Mark Irvin Rosenblatt Gene transfer methods and compositions
CA2492196C (en) * 2002-07-10 2009-12-01 Seikagaku Corporation Sulfotransferase inhibitors
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
EP1998177A3 (en) * 2003-01-06 2009-02-18 Wyeth Compositions and methods for diagnosing and treating colon cancers
EP1624858B1 (en) * 2003-04-09 2018-06-06 Rutgers, the State University of New Jersey Novel encochleation methods
EP1718767B1 (en) * 2004-02-03 2012-04-11 The Regents Of The University Of Michigan Compositions for treating breast and pancreatic cancer
US20050272682A1 (en) * 2004-03-22 2005-12-08 Evers Bernard M SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy
US7972295B2 (en) * 2005-03-11 2011-07-05 Boston Scientific Scimed, Inc. Apparatus and methods for delivering a bolus of therapeutic material
WO2007049361A1 (ja) * 2005-10-27 2007-05-03 Stelic Corp. 肝線維化抑制剤
US9308077B2 (en) * 2005-12-23 2016-04-12 Vysera Biomedical Limited Medical device suitable for treating reflux from a stomach to an oesophagus
CA2644513A1 (en) * 2006-03-03 2007-09-07 London Health Sciences Centre Research Inc. Preventing il-2 mediated inflammation in epithelial cells
KR20080102196A (ko) 2006-03-15 2008-11-24 도요다 지도샤 가부시끼가이샤 복수개의 육각셀로 구성된 허니콤 구조체
DK2002004T3 (en) * 2006-03-23 2015-11-30 Roche Innovation Ct Copenhagen As LITTLE INTERNAL SEGMENTED INTERFERENCE RNA
BRPI0709340A2 (pt) * 2006-03-27 2013-04-16 Globeimmune Inc mutaÇço ras e composiÇÕes e mÉtodos de uso da mesma
US20090275634A1 (en) * 2006-04-10 2009-11-05 Amarin Corporation Plc Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases
WO2007130604A2 (en) * 2006-05-04 2007-11-15 Baylor Research Institute Anti-tumor activity of an oncolytic adenovirus-delivered oncogene sirna
WO2008029493A1 (fr) * 2006-09-08 2008-03-13 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Inhibiteur de dégénération de fibres nerveuses
EP3045178A1 (en) * 2007-12-27 2016-07-20 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Sugar chain-related gene and use thereof
US20110275891A1 (en) * 2009-01-27 2011-11-10 Silenseed Ltd. Method and system for implant delivery

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0454352B2 (ja) 1983-01-18 1992-08-31 Sanyo Electric Co
JPH09505575A (ja) 1993-11-23 1997-06-03 ローン−プーラン・ロレ・ソシエテ・アノニム イン・ビボでの治療性生産物の生産のための組成物
JP2003516365A (ja) 1999-12-08 2003-05-13 フアルマコンセプツ・エイビー 核酸送達系
JP2005503199A (ja) 2001-06-14 2005-02-03 クック インコーポレーテッド 脈管内フィルター
JP2007119498A (ja) 2001-11-05 2007-05-17 Seikagaku Kogyo Co Ltd 上皮膨隆高の維持用組成物
JP2005538943A (ja) 2002-05-03 2005-12-22 エフエムシー バイオポリマー エイエス 非ウイルス性遺伝子送達システム
JP2007502616A (ja) * 2003-08-18 2007-02-15 アイシス ファーマシューティカルズ インコーポレイテッド ジアシルグリセロールアシルトランスフェラーゼ２発現の調節
WO2005063293A1 (ja) * 2003-12-26 2005-07-14 Masatoshi Hagiwara Sr蛋白質のリン酸化制御方法、および、sr蛋白質の活性制御剤を有効成分とする抗ウイルス剤

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
AKAMO Y. ET AL.: "Chemotherapy targeting regional lymph nodes by gastric submucosal injection of liposomal adriamycin in patients with gastric carcinoma", JPN. J. CANCER RES., vol. 85, no. 6, 1994, pages 652 - 658, XP008129076 *
BERNSTEIN, E., NATURE, vol. 409, pages 363 - 366
BUZAYAN, J.M., NATURE, vol. 323, 1986, pages 349
ELBASHIR SM. ET AL., NATURE, vol. 411, 2001, pages 494 - 498
ENSHOSEI CHO SHIKKAN NO KAKKITEKI CHIRYOHO NI KANSURU RINSHO KENKYU HEISEI 17 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, 2006 *
FIRE, A. ET AL., NATURE, vol. 391, 1998, pages 806 - 811
HAMMOND, S.M. ET AL., SCIENCE, vol. 293, 2001, pages 1146 - 1150
HARIMOTO K.: "Hi-Virus.Vector ni yoru Boko eno IN VIVO Idenshi Donyuho", THE JOURNAL OF THE OSAKA CITY MEDICAL CENTER, vol. 48, no. 3-4, 1999, pages 435 - 442, XP008129075 *
HIRASHIMA; INOUE: "New Courses in Experimental Biochemistry", 1993, THE JAPANESE BIOCHEMICAL SOCIETY, article "Idenshi no Fukusei to Hatsugen", pages: 319 - 347
KAWAUCHI Y. ET AL.: "Naishikyo o Mochiita Rat DDS Choen ni Taisuru HGF Idenshi Donyu no Kokoromi", DIGESTIVE ORGAN AND IMMUNOLOGY, no. 43, 2006, pages 98 - 101 *
KIHARA M, GUT., vol. 52, 2003, pages 713 - 9
KIKUCHI, Y.; KAGAKU TO SEIBUTSU, CHEMISTRY AND BIOLOGY, vol. 30, 1992, pages 112
KIKUCHI, Y.; SASAKI, N., NUCL ACIDS RES., vol. 19, 1991, pages 6751
KOIZUMI, M. ET AL., FEBS LETT., vol. 239, 1988, pages 285
KOIZUMI, M. ET AL., NUCL. ACIDS RES., vol. 17, 1989, pages 7059
KOIZUMI, M.; OTSUKA, E., PROTEIN, NUCLEIC ACID, AND ENZYME, vol. 35, 1990, pages 2191
OKAYASU I; HATAKEYAMA S; OHKUSA T; INAGAKI Y; NAKAYA R: "A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice", GASTROENTEROLOGY, vol. 98, 1990, pages 694 - 702
PUCILOWSKA JB ET AL., AM J PHYSIOL GASTROENTEROL LIVER PHYSIOL., vol. 279, 2000, pages G653 - G659
ROSIE Z ET AL., ANALYTICAL BIOCHEM., vol. 304, 2002, pages 19 - 25
SASAKI N, J INFLAMM., vol. 2, 2005, pages 13
See also references of EP2172226A4
SUZUKI K.: "Enshosei Cho Shikkan ni Taisuru HGF Oyobi HGF Idenshi o Mochiita Nenmaku Saisei Ryoho no Kaihatsu", ENSHOSEI CHO SHIKKAN NO KAKKITEKI CHIRYOHO NI KANSURU RINSHO KENKYU HEISEI 17 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, 2006, pages 31 - 34 *
SUZUKI K.: "Enshosei Cho Shikkan ni Taisuru Yakuzai no Naishikyoteki Shokakan Nenmakuka Chunyu Ryoho no Kaihatsu", ENSHOSEI CHOSHIKKAN NA KAKKITEKI CHIRYOHO NI KANSURU RINSHO KENKYU HEISEI 18 NENDO SOKATSU.BUNTAN KENKYU HOKOKUSHO, March 2007 (2007-03-01), pages 16 - 19 *
TAKEHARA T. ET AL.: "In vivo gene transfer and expression in rat stomach by submucosal injection of plasmid DNA", HUMAN GENE THERAPY, vol. 7, no. 5, 1996, pages 589 - 593, XP008129050 *
TIAN XH ET AL., HEPATOBILIARY PANCREAT DIS INT., vol. 4, 2005, pages 524
ZAMORE PD. ET AL., CELL, vol. 101, 2000, pages 25 - 33

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3673910A1 (en) * 2007-12-27 2020-07-01 Stelic Institute Of Regenerative Medicine, Stelic Institute & Co. Sugar chain-related gene and use thereof
US12239767B2 (en) 2009-10-23 2025-03-04 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
US11744927B2 (en) 2009-10-23 2023-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Dissolvable microneedle arrays for transdermal delivery to human skin
JP2015515886A (ja) * 2012-05-01 2015-06-04 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 経皮挿入するための先端装填型マイクロニードルアレイ
US9944019B2 (en) 2012-05-01 2018-04-17 University of Pittsburgh—of the Commonwealth System of Higher Education Tip-loaded microneedle arrays for transdermal insertion
WO2014013535A1 (ja) * 2012-07-17 2014-01-23 株式会社ステリック再生医科学研究所 粘膜治癒促進剤
JPWO2014013535A1 (ja) * 2012-07-17 2016-06-23 株式会社ステリック再生医科学研究所 粘膜治癒促進剤
EP3693462A1 (en) * 2012-07-17 2020-08-12 Stelic Institute&Co. Mucosal healing promoter
EP3878962A1 (en) * 2012-07-17 2021-09-15 Stelic Institute & Co. Mucosal healing promoter
US10441768B2 (en) 2015-03-18 2019-10-15 University of Pittsburgh—of the Commonwealth System of Higher Education Bioactive components conjugated to substrates of microneedle arrays
US10737083B2 (en) 2015-03-18 2020-08-11 University of Pittsburgh—of the Commonwealth System of Higher Education Bioactive components conjugated to dissolvable substrates of microneedle arrays
US11672964B2 (en) 2015-03-18 2023-06-13 University of Pittsburgh—of the Commonwealth System of Higher Education Bioactive components conjugated to substrates of microneedle arrays
US11684763B2 (en) 2015-10-16 2023-06-27 University of Pittsburgh—of the Commonwealth System of Higher Education Multi-component bio-active drug delivery and controlled release to the skin by microneedle array devices
US10646579B2 (en) 2015-11-04 2020-05-12 Tme Therapeutics Inc. Complex comprising RNAi molecule and N-acetylated chitosan
US11744889B2 (en) 2016-01-05 2023-09-05 University of Pittsburgh—of the Commonwealth System of Higher Education Skin microenvironment targeted delivery for promoting immune and other responses
US11911409B2 (en) 2016-12-07 2024-02-27 Stelic Institute & Co., Inc. Pharmaceutical composition for treatment and prevention of chronic disease
WO2018105708A1 (ja) 2016-12-07 2018-06-14 株式会社ステリック再生医科学研究所 慢性疾患の治療及び予防用医薬組成物
US12214150B2 (en) 2019-05-16 2025-02-04 University of Pittsburgh—of the Commonwealth System of Higher Education Microneedle arrays with undercut features for cutaneous and non-cutaneous drug delivery
EP4397310A4 (en) * 2021-08-30 2025-06-25 TME Therapeutics Inc. Pharmaceutical composition for suppressing cancer invasion and method for suppressing cancer invasion

Also Published As

Publication number Publication date
US20160355818A1 (en) 2016-12-08
EP2638917A1 (en) 2013-09-18
EP2172226A4 (en) 2010-06-30
JPWO2009004995A1 (ja) 2010-08-26
ES2685636T3 (es) 2018-10-10
US20100329993A1 (en) 2010-12-30
EP3284486A1 (en) 2018-02-21
EP3456357A1 (en) 2019-03-20
EP3034095A1 (en) 2016-06-22
US20190153447A1 (en) 2019-05-23
US20140135379A1 (en) 2014-05-15
EP3711755A1 (en) 2020-09-23
EP3034095B1 (en) 2018-08-08
JP5547964B2 (ja) 2014-07-16
EP2172226A1 (en) 2010-04-07
US20210040478A1 (en) 2021-02-11
US11485974B2 (en) 2022-11-01
US10689650B2 (en) 2020-06-23
EP3895737A1 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
NO20073456L (no) Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
NZ606825A (en) Methods and compositions for treating complement-associated disorders
WO2007009539A3 (en) Use of inhibitors of histone deacetylases in combination with nsaid for the therapy of cancer and/or inflammatory diseases
WO2010009116A3 (en) Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
TW200640497A (en) Pharmaceutical formulations and methods of use
EA200970360A1 (ru) Омега-3 жирные кислоты и средство для лечения дислипидемии для снижения уровней аро-в
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
WO2009120484A3 (en) Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
WO2008157103A3 (en) Modified release solid or semi-solid dosage forms
WO2010006219A3 (en) Use of scaffold comprising fibrin for delivery of stem cells
WO2007012022A3 (en) Unit dose form with ibuprofen-famotidine admixture
MX2009011900A (es) Curacion de herida diabetica.
WO2009022338A3 (en) Erythropoietin and fibronectin compositions for therapeutic and cosmetic applications
TW200833367A (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
WO2008109119A3 (en) Wnt compositions and methods of use thereof
WO2009129510A3 (en) Sulindac formulations in a biodegradable material
WO2012019188A3 (en) Methods and compositions for the inhibition of fructokinase
EP2236129A3 (en) Liposomal ALA Pharmaceutical and Cosmeceutical Compositions and Methods of Treatment
NZ591408A (en) Paracetamol and Calcium carbonate composition
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
CA2899775C (en) Compositions and methods for pain relief without numbness

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790674

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009521604

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008790674

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12666983

Country of ref document: US